# Letermovir Use in Heart Transplant Recipients

> **NCT04904614** · PHASE4 · COMPLETED · sponsor: **Tufts Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Cytomegalovirus Disease
- Cytomegalovirus Infections
- Heart Transplant Infection
- Antiviral Toxicity
- Neutropenia

## Interventions

- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT04904614
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-05
- **Primary completion:** 2025-01-14
- **Final completion:** 2025-01-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04904614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04904614, "Letermovir Use in Heart Transplant Recipients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04904614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*